Trial · NCT04625985

Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.

NCT04625985, Phase 2, Completed, Laboratorios Silanes S.A. de C.V.

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Trials, record NCT04625985. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04625985

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.
NCT number: NCT04625985
Status: Completed
Phases: Phase 2
Enrollment: 20 participants, actual
Lead sponsor: Laboratorios Silanes S.A. de C.V.
Conditions: Severe Acute Respiratory Syndrome Coronavirus 2
Interventions: Metformin Glycinate, Placebo oral tablet
First posted: 2020-11-12
Last updated: 2021-04-08

Source ClinicalTrials.gov

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Viral load	Day 0 to Day 28 or patient discharge day	Assess differences in SARS-CoV-2 viral load between participants that receive placebo vs metformin glycinate
Primary	consciousness level	Day 0 to Day 28 or patient discharge day	Clinical status assessed by measurement of consciousness level: alertness
Primary	temperature	Day 0 to Day 28 or patient discharge day	Clinical status assessed by measurement of axillary body temperature in °C: \<37.2.
Primary	systolic blood pressure	Day 0 to Day 28 or patient discharge day	Clinical status assessed by measurement of systolic blood pressure in mmHg: \>90.
Primary	Oxigen saturation	Day 0 to Day 28 or patient discharge day	Clinical status assessed by measurement of oxygen saturation in %: \>90.
Primary	Heart rate	Day 0 to Day 28 or patient discharge day	Clinical status assessed by measurement of heart rate in beats per minute: \<100 bpm.
Primary	respiratory rate	Day 0 to Day 28 or patient discharge day	Clinical status assessed by measurement of respiratory rate in breaths per minute: \<24 bpm,
Primary	Days of hospitalization	Day 0 to Day 28 or patient discharge day	Assess length of hospitalization
Primary	Days of supplementary oxygen if applies	Day 0 to Day 28 or patient discharge day	Assess length of supplementary oxygen
Primary	Days of supplementary mechanical ventilation	Day 0 to Day 28 or patient discharge day	Assess length of mechanical ventilation

1 to 10 of 12Source ClinicalTrials.gov

See all 12 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers8

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
11756340	RESULT	PubMed
11960602	RESULT	PubMed
12086935	RESULT	PubMed
16308421	RESULT	PubMed
17941868	RESULT	PubMed
19538242	BACKGROUND	PubMed
20380657	BACKGROUND	PubMed
22974412	RESULT	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04625985

GET https://conductscience.org/api/trials/v1/NCT04625985/registered

API reference For AI assistants